


MARTINDALE PHARMACEUTICALS LIMITED

**Directors' Report and
Unaudited Financial Statements
for the period
1 July 2016 to 31 December 2017**

SATURDAY



A22 *A7GZKG14* 20/10/2018 #78
COMPANIES HOUSE

MARTINDALE PHARMACEUTICALS LIMITED

**Contents of the Financial Statements
for the period 1 July 2016 to 31 December 2017**

	Page
Company Information	1
Directors' Report	2
Balance Sheet and Income Statement	3
Notes to the Financial Statements	4

MARTINDALE PHARMACEUTICALS LIMITED

Company Information
for the period 1 July 2016 to 31 December 2017

Directors:

M C J Harris
R G Joannesse
P E Parry

Registered office:

Bampton Road
Harold Hill
Romford
Essex
RM3 8UG

Registered number:

01073169 (England and Wales)

MARTINDALE PHARMACEUTICALS LIMITED

Directors' Report
for the period 1 July 2016 to 31 December 2017

The directors present their report with the financial statements of the company for the period 1 July 2016 to 31 December 2017.

Directors

The directors shown below have held office during the whole of the period from 1 July 2016 to the date of this report.

M C J Harris
P E Parry

Other changes in directors holding office are as follows:

R G Joannesse - appointed 28 February 2017
J Grover - resigned 28 February 2017

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

On behalf of the board:


M C J Harris - Director

Date: 28 September 2018

Balance Sheet
31 December 2017

	2017 £	2016 £
Total assets less current liabilities	<u>-</u>	<u>-</u>
Capital and reserves		
Called up share capital	100	100
Retained earnings	<u>(100)</u>	<u>(100)</u>
	<u>-</u>	<u>-</u>

The company is entitled to exemption from audit under Section 480 of the Companies Act 2006 for the period ended 31 December 2017.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 28 September 2018 and were signed on its behalf by:

Michael Harris
M C J Harris - Director

Income Statement
for the period 1 July 2016 to 31 December 2017

During the financial year and the preceding financial year the company has not traded and has received no income and incurred no expenditure. Consequently, during those periods the company has made neither a surplus nor a deficit.

MARTINDALE PHARMACEUTICALS LIMITED

Notes to the Financial Statements for the period 1 July 2016 to 31 December 2017

1. Statutory information

Martindale Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

3. Ultimate controlling party

The ultimate parent undertaking is Financière Verdi III, a company incorporated in France,

Financière Verdi III prepares group financial statements and copies can be obtained from:

Financière Verdi III
194, Bureaux de la Colline
92213 Saint-Cloud - FRANCE

4. Contingent liabilities

The Company has guaranteed bank and other borrowings of a parent undertaking, Orphea Limited, amounting to £151.6 million (2016: £nil).